CA - Medexus Pharmaceuticals Inc. (MEDXF) Q4 2024 Earnings Call Transcript

2024-06-26 10:28:06 ET

Medexus Pharmaceuticals Inc. (MEDXF)

Q4 2024 Earnings Conference Call

June 26, 2024 08:00 AM ET

Company Participants

Victoria Rutherford - IR, Adelaide Capital

Kenneth d'Entremont - CEO

Marcel Konrad - CFO

Conference Call Participants

Andre Uddin - Research Capital

Michael Freeman - Raymond James

David Martin - Bloom Burton

Stefan Quenneville - Echelon Capital Markets

Julian Hung - Stifel

Presentation

Operator

Good morning, everyone, and welcome to the Medexus Pharmaceuticals Fourth Fiscal Quarter and 2024 Fiscal Year Conference Call. At this time, all participants are in a listen-only mode, and we will be opening for questions following the presentation. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to your host, Victoria Rutherford, Investor Relations at Medexus. Over to you.

Victoria Rutherford

Thank you, and good morning, everyone. Welcome to the Medexus Pharmaceuticals fourth quarter and fiscal 2024 earnings call. On the call this morning are Ken d'Entremont, Chief Executive Officer; and Marcel Konrad, Chief Financial Officer. If you have any additional questions after the conference call or would like further information about the company, please contact at 480-625-5772.

I would like to remind everyone that this discussion will include forward-looking information as defined in securities laws. Actual results may differ materially from historical results or results anticipated by the forward-looking information. In addition, this discussion will also include non-GAAP measures, such as adjusted net income and loss and adjusted EBITDA, which do not have any standardized meaning under IFRS, and therefore, may not be comparable to similar measures presented by other companies....

For further details see: